Molecular Imaging-guided Gene Therapy of Gliomas
Gene therapy of patients with glioblastoma using viral and non-viral vectors, which are applied by direct injection or convection-enhanced delivery (CED), appear to be satisfactorily safe. Up to date, only single patients show a significant therapeutic benefit as deduced from single long-term survivors. Non-invasive imaging by PET for the identification of viable target tissue and for assessment of transduction efficiency shall help to identify patients which might benefit from gene therapy, while non-invasive follow-up on treatment responses allows early and dynamic adaptations of treatment options. Therefore, molecular imaging has a critical impact on the development of standardised gene therapy protocols and on efficient and safe vector applications in humans.
KeywordsPositron Emission Tomography Gene Therapy Herpes Simplex Virus Type Thymidine Kinase Meet Positron Emission Tomography
Unable to display preview. Download preview PDF.
- Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca A (1999) Multimodal cancer treatment mediated by replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59:3861–3865PubMedGoogle Scholar
- Brock CS, Young H, O’Reilly SM et al (2000) Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82:608–615PubMedCrossRefGoogle Scholar
- Heiss WD, Pawlik G, Herholz K, Wagner R, Goldner H, Wienhard K (1984) Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 4:212–223PubMedGoogle Scholar
- Kleihues P, Cavenee W K (2000) Pathology and genetics of tumours of the nervous system (WHO). International Agency for Research on Cancer (IARC Press), LyonGoogle Scholar
- Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRefGoogle Scholar
- Preston-Martin S (1999) Epidemiology. In: Berger MS, Wilson CD (eds) The gliomas. Saunders, Philadelphia, pp 2–11Google Scholar
- Ross BD, Kim B, Davidson BL (1995) Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1:651–657PubMedGoogle Scholar
- Shand N, Weber F, Mariani L et al (1999) A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10: 2325–2335PubMedCrossRefGoogle Scholar